-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $183

Benzinga·04/03/2025 10:34:16
Listen to the news
Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $202 to $183.